(Q43195002)

15 November 2017

Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer (English)

1 reference

15 November 2017

Osamu Nakahara

1

1 reference

15 November 2017

Hiroshi Takamori

2

1 reference

15 November 2017

Hiroshi Tanaka

3

1 reference

15 November 2017

Yasuo Sakamoto

4

1 reference

15 November 2017

Yoshiaki Ikuta

5

1 reference

15 November 2017

Satoshi Furuhashi

6

1 reference

15 November 2017

Masayuki Watanabe

7

1 reference

15 November 2017

Toru Beppu

8

1 reference

15 November 2017

Masahiko Hirota

9

1 reference

15 November 2017

Keiichiro Kanemitsu

10

1 reference

15 November 2017

Hideo Baba

11

1 reference

15 November 2017

language of work or name

1 reference

1 February 2010

1 reference

International Journal of Clinical Oncology

15 November 2017

1 reference

15 November 2017

15

1 reference

15 November 2017

1

1 reference

15 November 2017

39-45

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-009-0008-2

15 November 2017

0 references

cites work

Evaluation of sensitivity to 5-FU on the basis of thymidylate synthase (TS)/dihydropyrimidine dehydrogenase (DPD) activity and chromosomal analysis in micro tissue specimens of breast cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10147-009-0008-2

Treatment for pancreatic cancer: current therapy and continued progress

21 January 2018

1 reference

12 December 2020

High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.

1 reference

12 December 2020

A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil

1 reference

12 December 2020

Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1

1 reference

12 December 2020

Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma

1 reference

12 December 2020

Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer

1 reference

12 December 2020

Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival

1 reference

12 December 2020

Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?

1 reference

12 December 2020

Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer

1 reference

12 December 2020

Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells

1 reference

12 December 2020

The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer

1 reference

12 December 2020

DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.

1 reference

12 December 2020

5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer

1 reference

12 December 2020

Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer

1 reference

12 December 2020

Patterns of failure after curative resection of pancreatic carcinoma

1 reference

12 December 2020

Genetic factors influencing pyrimidine-antagonist chemotherapy.

1 reference

12 December 2020

Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors

1 reference

12 December 2020

Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study

1 reference

12 December 2020

In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.

1 reference

12 December 2020

Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer

1 reference

12 December 2020

Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

1 reference

12 December 2020

Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.

1 reference

12 December 2020

Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.

1 reference

12 December 2020

The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.

1 reference

12 December 2020

Recurrence of exocrine pancreatic cancer--local or hepatic?

1 reference

12 December 2020

Enzymes of uracil catabolism in normal and neoplastic human tissues

1 reference

12 December 2020

Recurrence after resection for ductal adenocarcinoma of the pancreas

1 reference

12 December 2020

Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer

1 reference

12 December 2020

10.1007/S10147-009-0008-2

Identifiers

DOI

1 reference

Dimensions Publication ID

15 November 2017

0 references

1 reference